Aspirin and Cancer Prevention (2026): New Evidence Shift in 20 Years

By Editorial Team -

Introduction: A Turning Point in Aspirin Oncology

Aspirin, originally developed by Bayer, is no longer just a cardiovascular drug being “repurposed” for cancer research.

In 2025–2026, oncology entered a new phase: a genetically stratified randomized trial showing real, clinically meaningful cancer recurrence reduction.

This is best exemplified by the landmark trial published in the New England Journal of Medicine:

👉 NEJM 2025; DOI: 10.1056/NEJMoa2504650



Section 1: The NEJM 2025 Breakthrough Trial (Game-Changing Evidence)

Trial Overview

A double-blind, placebo-controlled randomized trial evaluated aspirin in patients with resected colorectal cancer carrying PI3K pathway alterations.

Key design features:

  • Population: Stage I–III colorectal cancer

  • Biomarker selection: PI3K pathway mutations (including PIK3CA, PIK3R1, PTEN)

  • Intervention: Aspirin 160 mg daily vs placebo

  • Duration: 3 years

  • Endpoint: Cancer recurrence

📄 Full trial:
https://pubmed.ncbi.nlm.nih.gov/40961426/

Key Results

Primary outcome (PIK3CA hotspot subgroup):

  • Recurrence: 7.7% (aspirin) vs 14.1% (placebo)

  • Hazard ratio: 0.49

Broader PI3K pathway subgroup:

  • Recurrence reduction also significant

  • Hazard ratio: 0.42–0.51 range depending on subgroup

👉 Interpretation:
~50% reduction in recurrence in genetically defined patients

Clinical Meaning

This is the most important shift: Aspirin is no longer being evaluated as a general chemopreventive drug—it is emerging as a precision oncology intervention.

Supporting clinical summaries (NEJM clinical commentary, 2025) reinforce:

  • ~50% recurrence reduction in mutation-positive colorectal cancer

  • Strong signal in post-surgical adjuvant setting

  • Clinically actionable biomarker stratification

Section 2: Why This Trial Changes the Entire Field

This NEJM study resolves a key contradiction:

Before 2025:

  • Observational studies → strong benefit signals

  • RCTs → mostly neutral results

  • Guidelines → skeptical

After NEJM 2025:

  • Benefit exists—but only in defined genetic subgroups.

👉 This explains decades of conflicting data.

Section 3: Risk–Benefit Balance (Still the Limiting Factor)

Benefit

An updated 2025 systematic review and meta-analysis supports the growing body of evidence suggesting aspirin's potential role in reducing cancer incidence and mortality, particularly for colorectal and liver cancers.

Risk

Despite efficacy signals, risk remains unchanged:

Major risks:

  • GI bleeding

  • Intracranial hemorrhage

Supported by RCT meta-analysis (PMID: 33033530. 2020)

👉 Key insight: Even in genetically responsive patients, aspirin is:

  • Not universally safe

  • Not appropriate for unsupervised use.


The 2026 Unified Model of Aspirin in Cancer

All evidence now converges into a 3-layer model:

1. Genetic layer (NEJM 2025 breakthrough)

  • PI3K-altered tumors respond strongly

2. Microenvironment layer

  • Platelet suppression → immune activation

3. Systemic layer

  • Inflammation + oxidative stress modulation

Final Verdict (2026 Evidence Synthesis)

Aspirin’s role in oncology is no longer speculative.

It is now:

✔ A validated adjuvant therapy in PI3K-mutated colorectal cancer
✔ A potential anti-metastatic agent across tumor types
✔ A biologically multi-pathway modulator

But still:

✘ Not a general cancer prevention drug
✘ Not risk-free
✘ Not universally applicable

Bottom Line

The NEJM 2025 trial marks a paradigm shift: aspirin works—but only in the right biology, at the right time, in the right patient.


Related: 

Comments

Post a Comment

Labels

Show more

Archive

Show more

Popular posts from this blog

Fenbendazole, Ivermectin and Mebendazole for Cancer: A Case Series of 708 Case Reports (April 2026 Update)

By Editorial Team -
Image
Table of Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Breast Cancer Success Stories  (115 cases) Brain Cancer (including Glioblastoma) (120 cases) Bile Duct Cancer (Cholangiocarcinoma)  (4 cases) Bladder Cancer Success Stories  (including kidney cancer) (32 cases) Cervical Cancer  (6 cases) Colorectal Cancer  (including Appendix cancer) (57 cases) Esophageal and Stomach cancer (23 cases) Endometrial Cancer (11 cases) Gastric (Stomach) cancer (see  Esophageal and Stomach Cancer ) (22 cases) Head and Neck Cancer (15 cases) Kidney Cancer Case Series  (including urinary (urothelial) bladder cancer) (32 cases) Liver Cancer (HepatoCellular Cancer)  (3 cases) Lung Cancer (43 cases) Leukemia (9 cases) Lymphoma (23 cases) Melanoma (refer to Skin Cancer ) ...
Read more

Ivermectin and Fenbendazole: Treating Turbo Cancer - Dr William Makis

By Editorial Team -
Image
Ivermectin Resources I have seen tremendous demand for some sort of initial guidance “WHERE TO START” with High Dose Ivermectin for CANCER. Editor's Note: Dr Makis proposes four distinct cancer protocols for using Ivermectin in cancer treatment, specifically for patients who have developed turbo cancer or aggressive cancers. These protocols, referred to as the “Dr. Makis Ivermectin Cancer Protocols,” are categorized based on dosage and the severity of the cancer. Updated version I have an article and a video that go into depth: June 10, 2024 - "15 minutes with Dr.Makis" - Episode 018: High Dose Ivermectin and Cancer .  2025 - 2026 studies on ivermectin for cancer Clinical Yuan Yuan et al (Cedars-Sinai Medical Center) - A phase I/II study evaluating the safety and efficacy of ivermectin in combination with balstilimab in patients with metastatic triple negative breast cancer (ASCO 2025) Hulscher et al -  Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer ...
Read more

Ivermectin, Fenbendazole and Mebendazole Protocol in Cancer: Peer-Reviewed Protocol in Cancer

By Editorial Team -
Image
Medically Reviewed by: OneDayMD Editorial Team Last Updated: April 2026 We are pleased to announce that the first-of-its-kind protocol utilizing Ivermectin, Mebendazole, and Fenbendazole for cancer treatment has been peer-reviewed and officially published on September 19, 2024. Spearheaded by leading researchers like Dr. Ilyes Baghli, Dr. Pierrick Martinez, and the FLCCC’s Dr. Paul Marik, this groundbreaking protocol harnesses the untapped power of Ivermectin, Mebendazole, and Fenbendazole, known for their effectiveness against parasites. Now, these drugs are showing potential to battle cancer, marking the dawn of a new treatment evolution. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against c...
Read more

Fenbendazole Joe Tippens Protocol: A Step-by-Step Guide (2026)

By Editorial Team -
Image
If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories . We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discovered, through trial and error, a product in their canine product line, fenbendazole, that was batting 1.000 in killing these different cancers in the mice. The scientist was later diagnosed wit...
Read more

Dr William Makis Ivermectin Protocol 2026 – Complete Guide + Patient Outcomes

By Editorial Team -
Image
Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) runs the world's largest high-dose ivermectin cancer clientele in 2025 – he has guided thousands of patients globally with remarkable results in turbo cancers and conventional failures. This continuously updated 2026 guide compiles Dr. Makis's latest protocols (from his Substack, X posts through 2026, and direct patient correspondence). We cross-reference his exact dosages, schedules, combinations, safety data, sourcing, and real patient outcomes (anonymized but verifiable on his channels). Important Disclaimer: This content is for educational purposes only and does not constitute medical advice. Ivermectin is used off-label for cancer treatment. Always consult with a knowledgeable physician whom you trust to manage your health. Individual results may vary. Do not self-medicate with ivermectin without proper bloodwork and medical monitoring, as misuse can lead to serious side effects and drug interactions. ...
Read more

Ivermectin Tested against 28 types of Cancer: Most Sensitive vs Least Sensitive

By Editorial Team -
Image
A research group from Mexico investigated Ivermectin in Cancer. This is the first study that has tested as many as 28 Cancer types with Ivermectin.  Paper: 2020 (Juarez et al) - Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug.  Ivermectin was tested at 2mg/kg/day which translates to roughly 5uM in vitro concentration. The most sensitive cancer cell lines were: 1. Ovarian 2. Breast 3. Glioblastoma 4. Lung Cancer 5. Colon Cancer 6. Uterine SCC 7. hepatocellular 8. breast TNBC 9. Pancreatic 10. Endometrial. Least sensitive were: 1. osteosarcoma 2. gastric 3. melanoma  Although lymphoma and leukemia cell lines appear to be more resistant to Ivermectin, Ivermectin has a significant impact on those cells' ability to form colonies. So yes, Ivermectin is useful against BOTH lymphomas and leukemias.  Ivermectin also goes after CANCER STEM CELLS, which tend to be resistant to chemotherapy: ...
Read more

Best Ivermectin Dosage for Humans with Cancer or Different Cancer Types (2026)

By Editorial Team -
Image
Introduction This article discusses dosage considerations and key factors regarding the use of ivermectin in cancer treatment. Commonly available information about ivermectin dosages is often inaccurate when applied to potential cancer-related uses.  Many sources cite standard dosages recommended by Merck for treating parasitic infections, rather than dosages studied specifically in the context of cancer research. The anti-parasitic dosage is not as effective for people looking for a dosage against cancer. Dosage will need to be adjusted according to the  current weight, the type of Cancer, the stage and grade of the Cancer and the health of the liver. Ivermectin dosage should also be based on ivermectin cancer studies. Multiple factors are considered including studies including ivermectin for cancer, anecdotal studies and case series, the aggressiveness of the cancer type and the cancer stage. It also takes into account the types of medications the person uses. For example, i...
Read more

Ivermectin Dosage Guide for Humans (2026)

By Editorial Team -
Image
In this Article : Overview of Ivermectin Dosage | Ivermectin Dosage for Adults | Ivermectin Dosage for Children | Ivermectin dosage restrictions | How to take ivermectin | Ivermectin dosage FAQs The prescribed dosage for ivermectin oral tablets depends on the type of parasitic infection you have and your body weight. Ivermectin is typically taken as a single dose. Repeat doses may be needed in some cases. Specifically, ivermectin oral tablet is approved by the Food and Drug Administration (FDA) to treat the following conditions in adults and certain children: a parasitic infection in the intestinal tract called strongyloidiasis a parasitic infection of the eyes and skin called onchocerciasis  (River Blindness) Ivermectin oral tablet is a generic medication and belongs to a drug class called antiparasitic medications. It is also available in a brand-name version called Stromectol. This article describes the dosages of ivermectin oral tablets, as well as the medication’s stren...
Read more

DMSO 101: Benefits, Uses, Dosage and Side Effects (2026)

By Editorial Team -
Image
In 2022, Erica Eyres, a vigorous fifty-six-year-old aerobics instructor who had struggled to breathe, was given “absolutely devastating” news: She might need a lung transplant. She had never smoked, ran cross-country track in high school, and was a personal trainer for years, but, by 2024, a transplant assessment was arranged. “I decided that I will make that decision,” she said, “only if it’s the last resort, and I’m on my deathbed.” A few months before her consultation, however, Eyres, then fifty-eight, made an appointment with a new primary care doctor for routine prescription refills. She was about to be introduced, literally and figuratively, to a new kind of medicine. It would change everything. DMSO Online Buying Guide (Paid Link) Buy on Amazon Disclosure: OneDayMD.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program that enables sites to earn advertising fees by advertising and linking to Amazon.com, but this is at NO extra cost t...
Read more

Best Fenbendazole Dosage for Humans: Safety, Side Effects and Efficacy Examined (2026)

By Editorial Team -
Image
Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some fenbendazole advanced cancer success stories  (more than 500 case reports). Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different m...
Read more